ADHD

ADHD as a High-Volume Primary Care Condition

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children, adolescents, and adults. It is characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with daily functioning or development.^[1] For the Family Nurse Practitioner (FNP), this is a high-volume condition in primary care, making accurate diagnosis, appropriate pharmacologic management, and ongoing monitoring essential skills for board exams and clinical practice.

Core Diagnostic Parameters of ADHD

• Neurodevelopmental Disorder: Onset occurs during the developmental period, typically before age 12, but may not be recognized until adulthood.^[1]
• Executive Function Deficits: The core underlying impairment, involving working memory, emotional regulation, organization, and task initiation.
• DSM-5-TR Presentations:
  • Predominantly Inattentive (ADHD-I): Difficulty sustaining attention, easily distracted, forgetful.
  • Predominantly Hyperactive-Impulsive (ADHD-HI): Fidgeting, restlessness, talking excessively, difficulty waiting turns.
  • Combined (ADHD-C): Meets criteria for both inattention and hyperactivity-impulsivity.
• Differential Diagnosis: Anxiety disorders, mood disorders (bipolar), sleep apnea, learning disabilities, oppositional defiant disorder (ODD), and adjustment disorders must be ruled out.

Diagnostic Algorithm and Pathophysiology of ADHD

Pathophysiology

• Dysregulation of dopamine and norepinephrine neurotransmitter systems in the prefrontal cortex.^[5]
• Strong genetic component (heritability around 70-80%).^[5]

Diagnostic Algorithm

1. Clinical Interview: Assess symptom onset, duration, severity, and pervasiveness across settings (home, school, work).
2. Collateral Information: Obtain rating scales and feedback from parents, teachers, or partners.
3. Symptom Count: Must meet DSM-5-TR threshold (≥6 symptoms for children <17; ≥5 for adults ≥17).^[1]
4. Rule out Mimics: Screen for hyperthyroidism, lead toxicity, substance use, and adverse childhood events (ACEs).
5. Comorbidities: Identify co-occurring conditions (anxiety, depression, ODD, specific learning disorder) which are present in up to 60% of patients.^[2]

Age-Specific ADHD Symptomatology

In Children

• Inattention: Makes careless mistakes, does not listen when spoken to, loses items needed for tasks.
• Hyperactivity: Fidgets with hands/feet, leaves seat in classroom, "on the go" as if driven by a motor.
• Impulsivity: Blurts out answers before question is complete, interrupts conversations, difficulty waiting for turn.

In Adults and Adolescents

• Executive Dysfunction: Chronic procrastination, poor time management, difficulty with multitasking.
• Internalized Hyperactivity: Inner restlessness, inability to relax, excessive talking.
• Mood Lability: Low frustration tolerance, irritability, emotional reactivity.
• High-Risk Behaviors: Reckless driving, substance abuse, financial impulsivity.

Comprehensive Diagnostic Workup for ADHD

Diagnostic Criteria (DSM-5-TR)

• Symptom Threshold: Must have at least 6 symptoms of inattention or hyperactivity-impulsivity (5 for adults).
• Duration: Symptoms present for at least 6 months.
• Age of Onset: Several symptoms present before age 12.
• Settings: Present in 2 or more settings (home, school, work, social).
• Impairment: Clear evidence of interference with social, academic, or occupational functioning.^[1]

Screening Tools

• Children: Vanderbilt Assessment Scale (parent and teacher versions), Conners Rating Scales.
• Adults: Adult ADHD Self-Report Scale (ASRS-v1.1).

Physical Exam

• Vitals: Measure BP, HR, height, and weight (baseline for medication monitoring).
• Cardiac Screen: Auscultate for murmurs; assess for family history of sudden cardiac death or Long QT syndrome.^[3]
• Neurologic Exam: Evaluate for tics or other neurological soft signs.

Evidence-Based Management of ADHD Across the Lifespan

Multimodal Treatment Framework

The gold standard combines behavioral interventions with pharmacotherapy. The plan is age-dependent:^[2][4]

• Preschoolers (4-5 years): First-line is behavioral therapy (parent training in behavior management).
• School-Age (6-12 years): FDA-approved pharmacotherapy (stimulants) is strongly recommended, ideally combined with classroom behavioral interventions.
• Adolescents (13-18 years): Medication plus psychotherapy (cognitive behavioral therapy). Assess for substance use and diversion risk.
• Adults (≥18 years): Medication remains first-line, combined with organizational skills training and CBT.

Pharmacotherapy

Monitoring (Follow-Up Visits)

• Vital Signs Every Visit: Blood pressure and heart rate (risk of sustained hypertension).
• Growth: Height and weight plotted on growth curves (risk of appetite suppression).
• Symptom Response: Use repeat Vanderbilt or ASRS to track efficacy.
• Adverse Effects: Ask about sleep disturbance, mood changes, and tics.

Critical Safety Issues in ADHD Pharmacotherapy

• Cardiovascular: Contraindicated in patients with symptomatic cardiovascular disease, structural heart defects, or severe hypertension. Obtain EKG if family history of early cardiac death or abnormal cardiac exam.^[2]
• Psychiatric: Stimulants may precipitate psychosis, mania, or aggression. Screen for bipolar risk factors. Atomoxetine requires monitoring for suicidal ideation (especially in children/adolescents).
• Substance Abuse/Diversion: Stimulants are CII drugs with high abuse potential. Assess patient and family history of substance use disorder. Use prescription drug monitoring programs (PDMP).
• Growth Suppression: Monitor closely. Consider drug holidays or transitioning to non-stimulant if height velocity decreases significantly.
• Pregnancy: Risks vs. benefits must be weighed. Data on stimulant safety in pregnancy is limited; non-pharmacologic treatments are preferred.

ADHD Examination Priorities and Common Pitfalls

• First step for preschoolers (4-5): Behavioral therapy. This is a high-yield board question.
• First-line medication for all ages: Stimulants (methylphenidate or amphetamine formulations).
• Contraindication pair: Stimulants + MAOI within 14 days = hypertensive crisis.
• Vital Signs: Always check BP and HR at follow-up. This is a common test point and clinical safety measure.
• Black Box Warning (Atomoxetine): Increased risk of suicidal thoughts in children/adolescents. Counsel families.
• Differential: If a child has poor concentration and disruptive behavior, ALWAYS rule out sleep apnea, anxiety, and trauma before diagnosing ADHD.
• Adults: Must have documented symptoms before age 12 to make the diagnosis.
• Comorbidity: Up to 30-50% of children with ADHD have a co-existing learning disorder. Educational testing is important.
• Prescription Rules (CII): No refills allowed; must have a new written or electronic prescription every 30 days.

References

1. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). Arlington, VA: American Psychiatric Publishing. https://doi.org/10.1176/appi.books.9780890425787
2. Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., ... & Zurhellen, W. (2019). Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144(4), e20192528. https://doi.org/10.1542/peds.2019-2528
3. Felt, B. T., Biermann, B., Christner, J. G., Kochhar, P., & Van Harrison, R. (2019). Diagnosis and management of ADHD in children. American Family Physician, 99(11), 682-689. https://www.aafp.org/pubs/afp/issues/2019/0601/p682.html
4. Canadian ADHD Resource Alliance (CADDRA). (2020). Canadian ADHD Practice Guidelines (4th ed.). Toronto, ON: CADDRA. https://www.caddra.ca/wp-content/uploads/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf
5. Faraone, S. V., & Larsson, H. (2019). Genetics of attention deficit hyperactivity disorder. Molecular Psychiatry, 24(4), 562-575. https://doi.org/10.1038/s41380-018-0070-0
6. Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., ... & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5(9), 727-738. https://doi.org/10.1016/S2215-0366(18)30269-4